Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study

An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression

(2016) Suresh Durgam et al.   AMERICAN JOURNAL OF PSYCHIATRY

Efficacy and Safety of Adjunctive Cariprazine in Inadequate Responders to Antidepressants

(2016) Suresh Durgam et al.   JOURNAL OF CLINICAL PSYCHIATRY

Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO

(2016) Ragy R. Girgis et al.   PSYCHOPHARMACOLOGY

Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial

(2016) Suresh Durgam et al.   SCHIZOPHRENIA RESEARCH

P.3.d.053 Cariprazine as monotherapy for the treatment of schizophrenia patients with predominant negative symptoms: a double-blind, active controlled trial

(2015) M. Debelle et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Cariprazine in Acute Exacerbation of Schizophrenia

(2015) Suresh Durgam et al.   JOURNAL OF CLINICAL PSYCHIATRY

Occupancy of Dopamine D3 Receptors by Aripiprazole in Treatment Resistant Late-Life Depressed Patients Depends on Length of Treatment as Evidenced by in vivo Imaging with [11C]-(+)-PHNO

(2014) Fernando Caravaggio et al.   AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY

An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial

(2014) Suresh Durgam et al.   SCHIZOPHRENIA RESEARCH

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

(2013) Stefan Leucht et al.   LANCET

Cardiovascular side-effects of antipsychotic drugs: The role of the autonomic nervous system

(2012) Joanne Y.T. Leung et al.   PHARMACOLOGY & THERAPEUTICS

Cariprazine, a dopamine D3-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse

(2012) Ross Zimnisky et al.   PSYCHOPHARMACOLOGY

Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents

(2011) István Gyertyán et al.   NEUROCHEMISTRY INTERNATIONAL

Effects of antipsychotics on D3 receptors: A clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO

(2011) Romina Mizrahi et al.   SCHIZOPHRENIA RESEARCH

Antipsychotic Occupancy of Dopamine Receptors in Schizophrenia

(2010) Magdalena Nord et al.   CNS Neuroscience & Therapeutics

Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives

(2010) Haya Ascher-Svanum et al.   CURRENT MEDICAL RESEARCH AND OPINION

Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist-Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile

(2010) B. Kiss et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

The Effect of Antipsychotics on the High-Affinity State of D2 and D3 Receptors

(2009) Ariel Graff-Guerrero et al.   ARCHIVES OF GENERAL PSYCHIATRY

Akathisia: An Updated Review Focusing on Second-Generation Antipsychotics

(2009) John M. Kane et al.   JOURNAL OF CLINICAL PSYCHIATRY

Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15

(2008) István Gyertyán et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15

(2008) Béla Kiss et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY